CXD101

DB16182InvestigationalSmall molecule

CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).

Mechanism: Pharmacologically active on Histone deacetylase
Curator reviewed
Formula / weight: C₂₄H₂₉N₅O · 403.53 g/mol (avg)
Also known as: Hdac inhibitor cxd101 · Hdac-in-4
Code names: AZD-9468 · CXD-101

Resolves to

Compound

UNII5TNV87ICD2CAS934828-12-3ChEMBLCHEMBL4297489

Structure

InChIKeyJHDZMASHNBKTPS-UHFFFAOYSA-NSMILESCN1C=C(CN2CCC(CC2)C2=CC=C(C=C2)C(=O)NC2=CC=CC=C2N)C(C)=N1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which companies are running trials of CXD101, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account